Drug
Palbociclib plus fulvestrant
Palbociclib plus fulvestrant is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completed
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
NCT04916509
completed
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
NCT07096024
Clinical Trials (2)
Showing 2 of 2 trials
NCT04916509
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
NCT07096024
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2